The impact of luteinizing hormone and testosterone on beta amyloid (Aβ) accumulation: Animal and human clinical studies

Hormones and Behavior

Volumn 76, Issue , 2015, Pages 81-90

  Verdile, Giuseppe ^a,b,c   Asih, Prita R ^b,f   Barron, Anna M ^d   Wahjoepramono, Eka J ^c,e   Ittner, Lars M ^f,g   Martins, Ralph N ^a,b,c  

^a CURTIN UNIVERSITY   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^e PELITA HARAPAN UNIVERSITY   (Indonesia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Alzheimer's disease; Amyloid precursor protein beta amyloid; Luteinizing hormone; Testosterone

Indexed keywords

AMYLOID BETA PROTEIN; GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; NOOTROPIC AGENT; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; TESTOSTERONE DERIVATIVE; TRANSLOCATOR PROTEIN LIGAND; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ANDROGEN THERAPY; AROMATIZATION; ARTICLE; BIOACCUMULATION; COGNITION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG RESPONSE; HORMONAL REGULATION; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; MEMORY; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN TARGETING; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; LUTEINIZING HORMONE; TESTOSTERONE;

EID: 84947863632     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2015.05.020     Document Type: Article

References (136)

1. Aaronson A.J., Morrissey R.P., Nguyen C.T., Willix R., Schwarz E.R. Update on the safety of testosterone therapy in cardiac disease. Expert Opin. Drug Saf. 2011, 10:697-704.
2. Almeida O.P., Waterreus A., Spry N., Flicker L., Martins R.N. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology 2004, 29:1071-1081.
3. Asih P.R., Chatterjee P., Verdile G., Gupta V.B., Trengove R.D., Martins R.N. Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians. Neurodegener. Dis. Manag. 2014, 4:363-378.
4. Asih P.R., Wahjoepramono E.J., Aniwiyanti V., Wijaya L.K. Ruyck Kd, Taddei K, Fuller SJ, Sohrabi H, Dhaliwal SS, Verdile G, Carruthers M, Martins RN. Testosterone replacement therapy in older male subjective memory complainers: double-blind randomized crossover placebo-controlled clinical trial of physiological assessment and safety. CNS Neurol Disord Drug Targets 2015, 14(5):576-586.
5. Bagshawe K.D., Orr A.H., Rushworth A.G. Relationship between concentrations of human chorionic gonadotrophin in plasma and cerebrospinal fluid. Nature 1968, 217:950-951.
6. Barrett-Connor E. Male testosterone: what is normal?. Clin. Endocrinol. 2005, 62:263-264.
7. Barron A.M., Verdile G., Taddei K., Bates K.A., Martins R.N. Effect of chronic hCG administration on Alzheimer's-related cognition and A beta accumulation in PS1KI mice. Endocrinology 2010, 151:5380-5388.
8. Barron A.M., Garcia-Segura L.M., Caruso D., Jayaraman A., Lee J.W., Melcangi R.C., Pike C.J. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease. J. Neurosci. 2013, 33:8891-8897.
9. Bates K.A., Verdile G., Li Q.X., Ames D., Hudson P., Masters C.L., Martins R.N. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol. Psychiatry 2009, 14:469-486.
10. Berry A., Tomidokoro Y., Ghiso J., Thornton J. Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-beta levels in female rats. Horm. Behav. 2008, 54:143-152.
11. Bharadwaj P.R., Bates K.A., Porter T., Teimouri E., Perry G., Steele J.W., Gandy S., Groth D., Martins R.N., Verdile G. Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl. Psychiatry 2013, 3:e332.
12. Bhaskar K., Miller M., Chludzinski A., Herrup K., Zagorski M., Lamb B.T. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol. Neurodegener. 2009, 4:14.
13. Bi R., Broutman G., Foy M.R., Thompson R.F., Baudry M. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3602-3607.
14. Bowen R.L., Isley J.P., Atkinson R.L. An association of elevated serum gonadotropin concentrations and Alzheimer disease?. J. Neuroendocrinol. 2000, 12:351-354.
15. Bowen R.L., Smith M.A., Harris P.L., Kubat Z., Martins R.N., Castellani R.J., Perry G., Atwood C.S. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J. Neurosci. Res. 2002, 70:514-518.
16. Bowen R.L., Beaird H., Atwood C.S., Smith M.A., Rimm A.A. Men treated for prostate cancer have a decreased incidence of dementia. 9th International Congress on AD., Philadelphia, USA 2004.
17. Bowen R.L., Verdile G., Liu T., Parlow A.F., Perry G., Smith M.A., Martins R.N., Atwood C.S. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J. Biol. Chem. 2004, 279:20539-20545.
18. Bowen R.L., Perry G., Xiong C., Smith M.A., Atwood C.S. A clinical study of Lupron Depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose Lupron over 48weeks. J. Alzheimers Dis. 2015, 44(2):549-560.
19. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007, 3:186-191.
20. Bryan K.J., Mudd J.C., Richardson S.L., Chang J., Lee H.G., Zhu X., Smith M.A., Casadesus G. Down-regulation of serum gonadotropins is as effective as estrogen replacement at improving menopause-associated cognitive deficits. J. Neurochem. 2010, 112:870-881.
21. Burkhardt M.S., Foster J.K., Clarnette R.M., Chubb S.A., Bruce D.G., Drummond P.D., Martins R.N., Yeap B.B. Interaction between testosterone and apolipoprotein E epsilon4 status on cognition in healthy older men. J. Clin. Endocrinol. Metab. 2006, 91:1168-1172.
22. Butterfield D.A., Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 2001, 122:945-962.
23. Cappai R., Barnham K.J. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem. Res. 2008, 33:526-532.
24. Carroll J.C., Rosario E.R., Kreimer S., Villamagna A., Gentzschein E., Stanczyk F.Z., Pike C.J. Sex differences in beta-amyloid accumulation in 3xTg-AD mice: role of neonatal sex steroid hormone exposure. Brain Res. 2010, 1366:233-245.
25. Caruso D., Barron A.M., Brown M.A., Abbiati F., Carrero P., Pike C.J., Garcia-Segura L.M., Melcangi R.C. Age-related changes in neuroactive steroid levels in 3xTg-AD mice. Neurobiol. Aging 2013, 34:1080-1089.
26. Casadesus G., Webber K.M., Atwood C.S., Pappolla M.A., Perry G., Bowen R.L., Smith M.A. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim. Biophys. Acta 2006, 1762:447-452.
27. Casadesus G., Milliken E.L., Webber K.M., Bowen R.L., Lei Z., Rao C.V., Perry G., Keri R.A., Smith M.A. Increases in luteinizing hormone are associated with declines in cognitive performance. Mol. Cell. Endocrinol. 2007, 269:107-111.
28. Cherrier M.M., Asthana S., Plymate S., Baker L., Matsumoto A.M., Peskind E., Raskind M.A., Brodkin K., Bremner W., Petrova A., LaTendresse S., Craft S. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 2001, 57:80-88.
29. Cherrier M.M., Plymate S., Mohan S., Asthana S., Matsumoto A.M., Bremner W., Peskind E., Raskind M., Latendresse S., Haley A.P., Craft S. Relationship between testosterone supplementation and insulin-like growth factor-I levels and cognition in healthy older men. Psychoneuroendocrinology 2004, 29:65-82.
30. Cherrier M.M., Matsumoto A.M., Amory J.K., Asthana S., Bremner W., Peskind E.R., Raskind M.A., Craft S. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 2005, 64:2063-2068.
31. Cherrier M.M., Matsumoto A.M., Amory J.K., Johnson M., Craft S., Peskind E.R., Raskind M.A. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology 2007, 32:72-79.
32. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A.Y., Seubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992, 360:672-674.
33. D'Amico A.V., Braccioforte M.H., Moran B.J., Chen M.H. Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2010, 24:85-89.
34. De Felice F.G., Ferreira S.T. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes 2014, 63:2262-2272.
35. Desdouits-Magnen J., Desdouits F., Takeda S., Syu L.J., Saltiel A.R., Buxbaum J.D., Czernik A.J., Nairn A.C., Greengard P. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J. Neurochem. 1998, 70:524-530.
36. Drummond E.S., Harvey A.R., Martins R.N. Androgens and Alzheimer's disease. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16:254-259.
37. Dubey A.K., Herbert J., Abbott D.H., Martensz N.D. Serum and CSF concentrations of testosterone and LH related to negative feedback in male rhesus monkeys. Neuroendocrinology 1984, 39:176-185.
38. Ellis K.A., Bush A.I., Darby D., De Fazio D., Foster J., Hudson P., Lautenschlager N.T., Lenzo N., Martins R.N., Maruff P., Masters C., Milner A., Pike K., Rowe C., Savage G., Szoeke C., Taddei K., Villemagne V., Woodward M., Ames D., Group A.R. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int. Psychogeriatr. 2009, 21:672-687.
39. Emmelot-Vonk M.H., Verhaar H.J., Nakhai Pour H.R., Aleman A., Lock T.M., Bosch J.L., Grobbee D.E., van der Schouw Y.T. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008, 299:39-52.
40. Feneley M.R., Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J. Sex. Med. 2012, 9:2138-2149.
41. Fonte J., Miklossy J., Atwood C., Martins R. The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-beta Levels: resolubilization of amyloid-beta with transition metal ion chelators. J. Alzheimers Dis. 2001, 3:209-219.
42. Fuentealba R.A., Farias G., Scheu J., Bronfman M., Marzolo M.P., Inestrosa N.C. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res. Brain Res. Rev. 2004, 47:275-289.
43. Gandy S., Almeida O.P., Fonte J., Lim D., Waterrus A., Spry N., Flicker L., Martins R.N. Chemical andropause and amyloid-beta peptide. JAMA 2001, 285:2195-2196.
44. Gao W., Dalton J.T. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov. Today 2007, 12:241-248.
45. Gault P.M., Maudsley S., Lincoln G.A. Evidence that gonadotropin-releasing hormone II is not a physiological regulator of gonadotropin secretion in mammals. J. Neuroendocrinol. 2003, 15:831-839.
46. Gill S., Sharpless J.L., Rado K., Hall J.E. Evidence that GnRH decreases with gonadal steroid feedback but increases with age in postmenopausal women. J. Clin. Endocrinol. Metab. 2002, 87:2290-2296.
47. Gillett M.J., Martins R.N., Clarnette R.M., Chubb S.A., Bruce D.G., Yeap B.B. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J. Alzheimers Dis. 2003, 5:267-269.
48. Goodenough S., Engert S., Behl C. Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway. Neurosci. Lett. 2000, 296:49-52.
49. Gore A.C., Windsor-Engnell B.M., Terasawa E. Menopausal increases in pulsatile gonadotropin-releasing hormone release in a nonhuman primate (Macaca mulatta). Endocrinology 2004, 145:4653-4659.
50. Gouras G.K., Xu H., Gross R.S., Greenfield J.P., Hai B., Wang R., Greengard P. Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1202-1205.
51. Gruenewald D.A., Naai M.A., Marck B.T., Matsumoto A.M. Age-related decrease in hypothalamic gonadotropin-releasing hormone (GnRH) gene expression, but not pituitary responsiveness to GnRH, in the male Brown Norway rat. J. Androl. 2000, 21:72-84.
52. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
53. Haren M.T., Wittert G.A., Chapman I.M., Coates P., Morley J.E. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 2005, 50:124-133.
54. Hartmann H., Eckert A., Muller W.E. Disturbances of the neuronal calcium homeostasis in the aging nervous system. Life Sci. 1994, 55:2011-2018.
55. He D., Funabashi T., Sano A., Uemura T., Minaguchi H., Kimura F. Effects of glucose and related substrates on the recovery of the electrical activity of gonadotropin-releasing hormone pulse generator which is decreased by insulin-induced hypoglycemia in the estrogen-primed ovariectomized rat. Brain Res. 1999, 820:71-76.
56. Heneka M.T., Kummer M.P., Latz E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014, 14:463-477.
57. Hobbs C.J., Jones R.E., Plymate S.R. The effects of sex hormone binding globulin (SHBG) on testosterone transport into the cerebrospinal fluid. J. Steroid Biochem. Mol. Biol. 1992, 42:629-635.
58. Hogervorst E. Effects of gonadal hormones on cognitive behaviour in elderly men and women. J. Neuroendocrinol. 2013, 25:1182-1195.
59. Hogervorst E., Williams J., Budge M., Barnetson L., Combrinck M., Smith A.D. Serum total testosterone is lower in men with Alzheimer's disease. Neuro Endocrinol. Lett. 2001, 22:163-168.
60. Hogervorst E., Combrinck M., Smith A.D. Testosterone and gonadotropin levels in men with dementia. Neuro Endocrinol. Lett. 2003, 24:203-208.
61. Hogervorst E., Bandelow S., Combrinck M., Smith A.D. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp. Gerontol. 2004, 39:1633-1639.
62. Hogervorst E., Matthews F.E., Brayne C. Are optimal levels of testosterone associated with better cognitive function in healthy older women and men?. Biochim. Biophys. Acta 2010, 1800:1145-1152.
63. Holland J., Bandelow S., Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas 2011, 69:322-337.
64. Hyde Z., Flicker L., Almeida O.P., McCaul K.A., Jamrozik K., Hankey G.J., Chubb S.A., Yeap B.B. Higher luteinizing hormone is associated with poor memory recall: the health in men study. J. Alzheimers Dis. 2010, 19:943-951.
65. Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., Sandbrink R., Masters C.L., Beyreuther K. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J. Biol. Chem. 1996, 271:22908-22914.
66. Ittner L.M., Gotz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
67. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
68. Jayaraman A., Christensen A., Moser V.A., Vest R.S., Miller C.P., Hattersley G., Pike C.J. Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology 2014, 155:1398-1406.
69. Jones H.T. Testosterone Deficiency in Men 2012, Oxford University Press, Oxford, UK. Second ed.
70. Kaufman J.M., Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 2005, 26:833-876.
71. Kenny A.M., Fabregas G., Song C., Biskup B., Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59:75-78.
72. Krishnaswamy S., Verdile G., Groth D., Kanyenda L., Martins R.N. The structure and function of Alzheimer's gamma secretase enzyme complex. Crit. Rev. Clin. Lab. Sci. 2009, 46:282-301.
73. Krithivas K., Yurgalevitch S.M., Mohr B.A., Wilcox C.J., Batter S.J., Brown M., Longcope C., McKinlay J.B., Kantoff P.W. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J. Endocrinol. 1999, 162:137-142.
74. Lazzari C., Kipanyula M.J., Agostini M., Pozzan T., Fasolato C. Abeta42 oligomers selectively disrupt neuronal calcium release. Neurobiol. Aging 2015, 36(2):877-885.
75. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
76. Lee C., Ji I., Ryu K., Song Y., Conn P.M., Ji T.H. Two defective heterozygous luteinizing hormone receptors can rescue hormone action. J. Biol. Chem. 2002, 277:15795-15800.
77. Lee C., Ji I.J., Ji T.H. Use of defined-function mutants to access receptor-receptor interactions. Methods 2002, 27:318-323.
78. Lehmann D.J., Butler H.T., Warden D.R., Combrinck M., King E., Nicoll J.A., Budge M.M., de Jager C.A., Hogervorst E., Esiri M.M., Ragoussis J., Smith A.D. Association of the androgen receptor CAG repeat polymorphism with Alzheimer's disease in men. Neurosci. Lett. 2003, 340:87-90.
79. Lei Z.M., Rao C.V. Neural actions of luteinizing hormone and human chorionic gonadotropin. Semin. Reprod. Med. 2001, 19:103-109.
80. Li H.J., Zhou B.L., Bai L.L., Liu J.S., Huang Y.F. A tentative research of testosterone supplement therapy on male senile dementia. Zhonghua Nan Ke Xue 2003, 9:193-196.
81. Lin J., Li X., Yuan F., Lin L., Cook C.L., Rao Ch V., Lei Z. Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 2010, 69:253-261.
82. Lu F., Yang J.M., Wu J.N., Chen Y.C., Kao Y.H., Tung C.S., Yang S.N. Activation of gonadotropin-releasing hormone receptors produces neuronal excitation in the rat hippocampus. Chin. J. Physiol. 1999, 42:67-71.
83. Lu P.H., Masterman D.A., Mulnard R., Cotman C., Miller B., Yaffe K., Reback E., Porter V., Swerdloff R., Cummings J.L. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch. Neurol. 2006, 63:177-185.
84. Luchetti S., Bossers K., Van de Bilt S., Agrapart V., Morales R.R., Frajese G.V., Swaab D.F. Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer's disease. Neurobiol. Aging 2011, 32:1964-1976.
85. Lukacs H., Hiatt E.S., Lei Z.M., Rao C.V. Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cycling female rats. Horm. Behav. 1995, 29:42-58.
86. Manthey D., Heck S., Engert S., Behl C. Estrogen induces a rapid secretion of amyloid beta precursor protein via the mitogen-activated protein kinase pathway. Eur. J. Biochem. 2001, 268:4285-4291.
87. Matousek R.H., Sherwin B.B. Sex steroid hormones and cognitive functioning in healthy, older men. Horm. Behav. 2010, 57:352-359.
88. 2+ homeostasis in Alzheimer's disease. Trends Neurosci. 1993, 16:409-414.
89. McAllister C., Long J., Bowers A., Walker A., Cao P., Honda S., Harada N., Staufenbiel M., Shen Y., Li R. Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment. J. Neurosci. 2010, 30:7326-7334.
90. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 1999, 46:860-866.
91. Moffat S.D., Zonderman A.B., Metter E.J., Kawas C., Blackman M.R., Harman S.M., Resnick S.M. Free testosterone and risk for Alzheimer disease in older men. Neurology 2004, 62:188-193.
92. Muller W.E., Kirsch C., Eckert G.P. Membrane-disordering effects of beta-amyloid peptides. Biochem. Soc. Trans. 2001, 29:617-623.
93. Muller M., Aleman A., Grobbee D.E., de Haan E.H., van der Schouw Y.T. Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level?. Neurology 2005, 64:866-871.
94. Nalivaeva N.N., Belyaev N.D., Kerridge C., Turner A.J. Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. Front. Aging Neurosci. 2014, 6:235.
95. Nguyen T.V., Yao M., Pike C.J. Androgens activate mitogen-activated protein kinase signaling: role in neuroprotection. J. Neurochem. 2005, 94:1639-1651.
96. Nuruddin S., Syverstad G.H., Lillehaug S., Leergaard T.B., Nilsson L.N., Ropstad E., Krogenæs A., Haraldsen I.R., Torp R. Elevated mRNA-levels of gonadotropin-releasing hormone and its receptor in plaque-bearing Alzheimer's disease transgenic mice. PLoS One 2014, 9(8). e103607.
97. Oliveira S.M., Ribeiro C.A., Cardoso I., Saraiva M.J. Gender-dependent transthyretin modulation of brain amyloid-beta levels: evidence from a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2011, 27:429-439.
98. O'Malley T.T., Oktaviani N.A., Zhang D., Lomakin A., O'Nuallain B., Linse S., Benedek G.B., Rowan M.J., Mulder F.A., Walsh D.M. Abeta dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies. Biochem. J. 2014, 461:413-426.
99. Palm R., Chang J., Blair J., Garcia-Mesa Y., Lee H.G., Castellani R.J., Smith M.A., Zhu X., Casadesus G. Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J. Neurochem. 2014, 130:115-125.
100. Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapere J.J., Lindemann P., Norenberg M.D., Nutt D., Weizman A., Zhang M.R., Gavish M. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 2006, 27:402-409.
101. Pereira C., Ferreiro E., Cardoso S.M., de Oliveira C.R. Cell degeneration induced by amyloid-beta peptides: implications for Alzheimer's disease. J. Mol. Neurosci. 2004, 23:97-104.
102. Periti P., Mazzei T., Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin. Pharmacokinet. 2002, 41:485-504.
103. Raber J., Bongers G., LeFevour A., Buttini M., Mucke L. Androgens protect against apolipoprotein E4-induced cognitive deficits. J. Neurosci. 2002, 22:5204-5209.
104. Ramsden M., Nyborg A.C., Murphy M.P., Chang L., Stanczyk F.Z., Golde T.E., Pike C.J. Androgens modulate beta-amyloid levels in male rat brain. J. Neurochem. 2003, 87:1052-1055.
105. Rinnab L., Gust K., Hautmann R.E., Kufer R. Testosterone replacement therapy and prostate cancer. The current position 67years after the Huggins myth. Urologe A 2009, 48:516-522.
106. Rodrigues M.A., Verdile G., Foster J.K., Hogervorst E., Joesbury K., Dhaliwal S., Corder E.H., Laws S.M., Hone E., Prince R., Devine A., Mehta P., Beilby J., Atwood C.S., Martins R.N. Gonadotropins and cognition in older women. J. Alzheimers Dis. 2008, 13:267-274.
107. Rosario E.R., Chang L., Stanczyk F.Z., Pike C.J. Age-related testosterone depletion and the development of Alzheimer disease. JAMA 2004, 292:1431-1432.
108. Rosario E.R., Carroll J.C., Oddo S., LaFerla F.M., Pike C.J. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J. Neurosci. 2006, 26:13384-13389.
109. Rosario E.R., Chang L., Beckett T.L., Carroll J.C., Paul Murphy M., Stanczyk F.Z., Pike C.J. Age-related changes in serum and brain levels of androgens in male Brown Norway rats. Neuroreport 2009, 20:1534-1537.
110. Rosario E.R., Chang L., Head E.H., Stanczyk F.Z., Pike C.J. Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Neurobiol. Aging 2011, 32:604-613.
111. Rosario E.R., Carroll J.C., Pike C.J. Evaluation of the effects of testosterone and luteinizing hormone on regulation of beta-amyloid in male 3xTg-AD mice. Brain Res. 2012, 1466:137-145.
112. Rupprecht R., Papadopoulos V., Rammes G., Baghai T.C., Fan J., Akula N., Groyer G., Adams D., Schumacher M. Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat. Rev. Drug Discov. 2010, 9:971-988.
113. Scarf A.M., Ittner L.M., Kassiou M. The translocator protein (18kDa): central nervous system disease and drug design. J. Med. Chem. 2009, 52:581-592.
114. Shao T.C., Li H.L., Kasper S., Matusik R., Ittmann M., Cunningham G.R. Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. Prostate 2006, 66:369-376.
115. Short R.A., Bowen R.L., O'Brien P.C., Graff-Radford N.R. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin. Proc. 2001, 76:906-909.
116. Tan R.S., Pu S.J. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male 2003, 6:13-17.
117. Venken K., Boonen S., Van Herck E., Vandenput L., Kumar N., Sitruk-Ware R., Sundaram K., Bouillon R., Vanderschueren D. Bone and muscle protective potential of the prostate-sparing synthetic androgen 7alpha-methyl-19-nortestosterone: evidence from the aged orchidectomized male rat model. Bone 2005, 36:663-670.
118. Venneti S., Lopresti B.J., Wiley C.A. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog. Neurobiol. 2006, 80:308-322.
119. Verdier Y., Zarandi M., Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 2004, 10:229-248.
120. Verdile G., Yeap B.B., Clarnette R.M., Dhaliwal S., Burkhardt M.S., Chubb S.A., De Ruyck K., Rodrigues M., Mehta P.D., Foster J.K., Bruce D.G., Martins R.N. Luteinizing hormone levels are positively correlated with plasma amyloid-beta protein levels in elderly men. J. Alzheimers Dis. 2008, 14:201-208.
121. Verdile G., Laws S.M., Henley D., Ames D., Bush A.I., Ellis K.A., Faux N.G., Gupta V.B., Li Q.X., Masters C.L., Pike K.E., Rowe C.C., Szoeke C., Taddei K., Villemagne V.L., Martins R.N., Group A.R. Associations between gonadotropins, testosterone and beta amyloid in men at risk of Alzheimer's disease. Mol. Psychiatry 2014, 19:69-75.
122. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D.B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 1993, 61:1965-1968.
123. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L., Australian Imaging B., Lifestyle Research G. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
124. Wahjoepramono, E.J, Asih, P.R., Aniwiyanti, V, Wijaya L.K., Taddei K., Dhaliwal S.S, Fuller, S.J, Foster J, Carruthers M, Verdile G, Sohrabi H.R, Martins R.N. The Effects of Testosterone Supplementation on Cognitive Functioning in Older Men. Aging Male, (manuscript submitted).
125. Wahjoepramono E.J., Wijaya L.K., Taddei K., Martins G., Howard M., de Ruyck K., Bates K., Dhaliwal S.S., Verdile G., Carruthers M., Martins R.N. Distinct effects of testosterone on plasma and cerebrospinal fluid amyloid-beta levels. J. Alzheimers Dis. 2008, 15:129-137.
126. Wahjoepramono E.J., Wijaya L.K., Taddei K., Bates K.A., Howard M., Martins G., deRuyck K., Matthews P.M., Verdile G., Martins R.N. Direct exposure of guinea pig CNS to human luteinizing hormone increases cerebrospinal fluid and cerebral beta amyloid levels. Neuroendocrinology 2011, 94:313-322.
127. Walsh J.P., Kitchens A.C. Testosterone therapy and cardiovascular risk. Trends Cardiovasc. Med. 2015, 25(3):250-257.
128. Walsh D.M., Teplow D.B. Alzheimer's disease and the amyloid beta-protein. Prog. Mol. Biol. Transl. Sci. 2012, 107:101-124.
129. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10831-10839.
130. Wilson A.C., Salamat M.S., Haasl R.J., Roche K.M., Karande A., Meethal S.V., Terasawa E., Bowen R.L., Atwood C.S. Human neurons express type I GnRH receptor and respond to GnRH I by increasing luteinizing hormone expression. J. Endocrinol. 2006, 191:651-663.
131. Wood J.R., Strauss J.F. Multiple signal transduction pathways regulate ovarian steroidogenesis. Rev. Endocr. Metab. Disord. 2002, 3:33-46.
132. Yaffe K., Edwards E.R., Lui L.Y., Zmuda J.M., Ferrell R.E., Cauley J.A. Androgen receptor CAG repeat polymorphism is associated with cognitive function in older men. Biol. Psychiatry 2003, 54:943-946.
133. Yao M., Nguyen T.V., Rosario E.R., Ramsden M., Pike C.J. Androgens regulate neprilysin expression: role in reducing beta-amyloid levels. J. Neurochem. 2008, 105:2477-2488.
134. Yarram S.J., Perry M.J., Christopher T.J., Westby K., Brown N.L., Lamminen T., Rulli S.B., Zhang F.P., Huhtaniemi I., Sandy J.R., Mansell J.P. Luteinizing hormone receptor knockout (LuRKO) mice and transgenic human chorionic gonadotropin (hCG)-overexpressing mice (hCG alphabeta+) have bone phenotypes. Endocrinology 2003, 144:3555-3564.
135. Young L.A., Neiss M.B., Samuels M.H., Roselli C.E., Janowsky J.S. Cognition is not modified by large but temporary changes in sex hormones in men. J. Clin. Endocrinol. Metab. 2010, 95:280-288.
136. Ziegler S.G., Thornton J.E. Low luteinizing hormone enhances spatial memory and has protective effects on memory loss in rats. Horm. Behav. 2010, 58:705-713.